The latest advances in the use of biological DMARDs to treat Still's disease [0.03%]
生物DMARD在Still病治疗中的最新进展
Ilenia Di Cola,Piero Ruscitti
Ilenia Di Cola
Introduction: Currently, the therapeutic management of Still's disease, a multisystemic inflammatory rare disorder, is directed to target the inflammatory symptoms and signs of patients. The treatment varies from glucocor...
Pembrolizumab for metastatic castration-resistant prostate cancer: trials and tribulations [0.03%]
派姆单抗治疗转移性去势抵抗性前列腺癌：临床试验及其挑战
Alexander K Tsai,Sana Kagalwalla,Jenna Langer et al.
Alexander K Tsai et al.
Introduction: Immunotherapies have revolutionized the management of various malignancies but have only recently been evaluated systematically in prostate cancer. Pembrolizumab, a programmed-death 1 (PD-1) blocking antibod...
Pharmacokinetics and pharmacodynamics of the proposed biosimilar denosumab GP2411 and reference denosumab in healthy males [0.03%]
建议的 Denosumab 生物类似药 GP2411 和原研 Denosumab 在健康男性中的药代动力学和药效学研究
Barbara Vogg,Johann Poetzl,Rachid El Galta et al.
Barbara Vogg et al.
Background: This Phase I study compared the pharmacokinetic (PK) and pharmacodynamic (PD) similarity of GP2411 proposed denosumab biosimilar to reference denosumab (a monoclonal antibody for specific pro-resorptive condit...
Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study [0.03%]
乌司奴单抗对溃疡性结肠炎患者的安全性和有效性：一项大型现实研究的结果
Antonio Tursi,Giammarco Mocci,Franco Scaldaferri et al.
Antonio Tursi et al.
Background: Ustekinumab (UST) is an interleukin-12/interleukin-23 receptor antagonist recently approved for treating ulcerative colitis (UC) but with limited real-world data. Therefore, we evaluated the effectiveness and ...
Clinical advances in biological therapy for generalized pustular psoriasis: a review [0.03%]
广义脓疱型银屑病生物治疗的临床进展：一项回顾
Chang-Yu Hsieh,Tsen-Fang Tsai
Chang-Yu Hsieh
Introduction: In 2022, U.S. Food and Drug Administration (FDA) approved the first biologics, intravenous spesolimab, for acute flare of generalized pustular psoriasis (GPP). The drug works by blocking IL-36 signaling, the...
An overview of site-specific methods for achieving antibody drug conjugates with homogenous drug to antibody ratio [0.03%]
具有均匀药物抗体比的抗体药偶联物的定点偶联方法概述
Dina V Hingorani
Dina V Hingorani
Introduction: Antibody drug conjugates (ADCs) have emerged as a potent tool in cancer treatment, where cytotoxic drugs are linked to antibodies targeting specific antigens. While conventional ADC synthesis methods have se...
Ahmad Z Al Meslamani
Ahmad Z Al Meslamani
Introduction: Biosimilars are gaining popularity due to their ability to offer comparable therapeutic benefits at potentially lower costs. Areas covered: ...
Safety of dupilumab in T2 airways conditions: focus on eosinophilia across trials and real-life evidence [0.03%]
dupilumab在T2气道疾病条件下的安全性：关注试验和现实生活中嗜酸性粒细胞增多的情况
Marco Caminati,Claudio Micheletto,Francesca Norelli et al.
Marco Caminati et al.
Introduction: Dupilumab, a monoclonal antibody targeting the IL-4 receptor alpha subunit, effectively blocks both IL-4 and IL-13 mediated pathways. Its introduction has represented a significant advancement in the treatme...
Decoding treatment efficacy: uncovering response and failure dynamics to biologics in asthma [0.03%]
解码治疗效果：揭示哮喘生物制剂治疗的反应和失败动力学
Ahmad Z Al Meslamani
Ahmad Z Al Meslamani
Introduction: Asthma is a global health problem, with alarming prevalence and mortality rates. Biologic therapies, particularly monoclonal antibodies such as omalizumab, have emerged as promising alternatives, targeting s...
Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study [0.03%]
特拉鲁单抗治疗的大多数特应性皮炎患者达到当前治疗目标：一项多中心、多国、回顾性队列研究的结果
A Chiricozzi,S M Ferrucci,L Di Nardo et al.
A Chiricozzi et al.
Background: Tralokinumab is a human monoclonal antibody targeting interleukin-13 that is approved for the treatment of moderate-severe atopic dermatitis. Studies analyzing the efficacy and safety of tralokinumab in a real...